Inhibitor Therapeutics Inc
OTC:INTI
Inhibitor Therapeutics Inc
OTC:INTI
Price:
0.09
USD
-17.43%
Market Closed
Market Cap:
$15.5m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Inhibitor Therapeutics Inc
OTC:INTI
|
US |
|
C
|
China Railway Harbin Group of Technology Corp
SSE:688459
|
CN |
|
iMining Technologies Inc
XTSX:IMIN
|
CA |
|
Guangdong Taiantang Pharmaceutical Co Ltd
SZSE:002433
|
CN |
|
Katare Spinning Mills Ltd
BSE:502933
|
IN |
|
N
|
North Long Dragon New Materials Tech Co Ltd
SZSE:301357
|
CN |
|
Micreed Co Ltd
TSE:7687
|
JP |
|
Encision Inc
OTC:ECIA
|
US |
|
L
|
Lipidor AB
STO:LIPI
|
SE |
|
Z
|
Zhejiang Bangjie Holding Group Co Ltd
SZSE:002634
|
CN |
|
O
|
Omansh Enterprises Ltd
BSE:538537
|
IN |
|
B
|
Beijing SPC Environment Protection Tech Co Ltd
SZSE:002573
|
CN |
|
G
|
Geomega Resources Inc
OTC:GOMRF
|
CA |
|
Vongroup Ltd
HKEX:318
|
HK |
|
Nexus Gold Corp
XTSX:NXS
|
CA |
|
V
|
Vodatel Networks Holdings Ltd
HKEX:8033
|
MO |
|
E
|
EQV Ventures Acquisition Corp
NYSE:EQV
|
US |
|
G
|
Genes Tech Group Holdings Co Ltd
HKEX:8257
|
TW |
Multiples-Based Value
The
Multiples-Based Value for
Inhibitor Therapeutics Inc (INTI)
under the Base Case is
hidden
USD.
Compared with the current market price of 0.09 USD, the stock appears
hidden
.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
INTI Multiples-Based Value
LOCKED
Multiples Across Competitors
INTI Competitors Multiples
Inhibitor Therapeutics Inc Competitors
Inhibitor Therapeutics Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Inhibitor Therapeutics Inc
OTC:INTI
|
15.5m USD | 0 | -4.7 | -3.8 | -3.8 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
369.2B USD | 6 | 88.2 | 14.6 | 20.3 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
187.5B USD | 5.1 | 24.3 | 14.1 | 14.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
173.4B USD | 5.9 | 20.4 | 12.7 | 15.7 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
111.4B USD | 9.3 | 28.2 | 21.2 | 22.1 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
80.5B USD | 5.6 | 17.9 | 13.3 | 15.2 | |
| AU |
|
CSL Ltd
ASX:CSL
|
67B AUD | 3.1 | 34 | 11.3 | 14.2 | |
| NL |
|
argenx SE
XBRU:ARGX
|
39.6B EUR | 11.3 | 36.2 | 39.3 | 40.1 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
